Global Pharmatech, Inc. (GBLP)
- Previous Close
0.1500 - Open
0.1500 - Bid --
- Ask --
- Day's Range
0.1500 - 0.1500 - 52 Week Range
0.1100 - 0.2500 - Volume
1,000 - Avg. Volume
15 - Market Cap (intraday)
1.417M - Beta (5Y Monthly) -3.14
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Global Pharmatech, Inc. engages in the research, production, and development of herbal medicine, bio-medicine, chemical medicine, traditional chinese medicine, and dietary supplements primarily in China. The company's principal product line consists of XS CAPSULE (XIN-SHU) for the treatment of angina and other coronary disease; JUTAI SOFT CAPSULE, a dietary supplement; QINGXUAN ANTI-HYPERTENSION TABLET, an over-the-counter drug product indicated for the treatment of hypertension and high serum cholesterol level; and YANREQING TABLET for the treatment of inflammation. It also manufactures and sells other proprietary drugs, generics, and dietary supplements used to treat symptoms ranging from headaches, coughing, and dry mouth to infections, and numbness of limbs. The company markets its products through distributors, such as wholesale companies and chain store representatives, as well as through its sales force. Global Pharmatech, Inc. was founded in 2001 and is based in Changchun, China.
217
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: GBLP
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GBLP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GBLP
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
-0.44
Enterprise Value/EBITDA
0.06
Financial Highlights
Profitability and Income Statement
Profit Margin
-70.45%
Return on Assets (ttm)
-10.39%
Return on Equity (ttm)
-22.59%
Revenue (ttm)
3.18M
Net Income Avi to Common (ttm)
-2.24M
Diluted EPS (ttm)
-0.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
5.44M
Total Debt/Equity (mrq)
28.58%
Levered Free Cash Flow (ttm)
325.78k
Company Insights: GBLP
GBLP does not have Company Insights